scPharmaceuticals Inc. operates as a pharmaceutical company. The Company focuses on the development of subcutaneous furosemide and a cephalosporin antibiotic products for the treatment of worsening and heart failure of inpatient setting. scPharmaceuticals serves patients in the State of Massachusetts.

Current Report (Form 8-K | Period ending 2024-12-11)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

scPharmaceuticals Inc (SCPH US)

Current Report (Form 8-K | Period ending 2024-12-11)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-13)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-08-14)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)